Cytoplasmic retention renders this RAD52 variant nonfunctional leading apparently to attrition of BRCA2-deficient breast cancer cells (Adamson et al., 2020; Biswas and Sharan 2020). This evidence concerns the gene RAD52 and breast carcinoma.